Thursday, October 31, 2024 - Agenda

Learning Objectives:

• Discuss the current epidemiology of the opiate crisis
• Describe prescribing strategies for opiates that mitigate risk
• Discuss the role of the internal medicine specialist in medication assisted treatment

Marc G. Kaprow, DO, MHA, MACOI (he/him/his), Assistant Professor, Internal Medicine, University of Central Florida

Keynote: Lifestyle, Medicine, and Heart Disease

Steven Lome, DO (he/him/his), Chief of Cardiology, Montage Health

More details coming soon

Brian Lake, DO (he/him/his), Endocrinologist, Lake Endocrinology and Diabetes, PLLC

Learning Objectives:

• Recognize evidence based medicine approach to working up an incidental thyroid nodule.
• Recognize concerning thyroid nodule diagnosis.
• Understand cost effective work up and treatment for thyroid nodules

James Bonucchi, DO (he/him/his), Endocrinologist, CoxHealth, Springfield MO

Learning Objectives:

• Describe the differences between Normocalcemic Primary Hyperparathyroidism and secondary hyperparathyroidism
• Demonstrate appropriate use and interpretation of TBS trabecular Bone score 
• Define hypercalcemic crisis. 

Ania Janicka, DO, Practice Partner and Core Attending Endocrine Fellowship, Diabetes Care Center

Learning Objectives:

• Grasp the health importance that colorectal cancer poses to their patient population through incidence, mortality risk and differences in presentation depending on location. 
• List the FDA approved screening modalities for colorectal cancer available in the US and the pros and cons of each modality in their patient population to be able to guide them towards appropriate screening. 
• Understand the unique challenges facing select populations of patients at risk for this disease including early onset colorectal cancer, older adult patients as well as colorectal cancer survivors 

Joseph W. McCollom, DO (he/him/his), Oncologist

Learning Objectives:

• Have a better understanding of the common underlying mechanisms of CKM Syndrome and their multisystem manifestations 
• Describe the individual features and manifestation of specific end organ involvement in CKM 
• Be able to classify at risk patients for CKM Syndrome and list risk factors Understand and apply evidence-based early interventions and treatments to prevent or attenuate the systemic damage 

Mark D. Baldwin, DO, FACOI, FASN (he/him/his), Professor and Chair, Department of Internal Medicine

Learning Objectives:

• Upon completion, participant will be able to define Palliative Chemotherapy and goals of treatment.
• Upon completion, participant will be able to articulate non-cytotoxic medications with disease altering properties which provide symptomatic relief.
• Upon completion, participant will be familiar with non-cytotoxic target therapies that have anti-neoplastic effects.

Jason R. Beckrow, DO, FACOI, FAAHPM, HMDC (he/him/his), Assistant Professor

Learning Objectives:

• Determine appropriate breast cancer screening recommendations based on lifetime risk of breast cancer.
• Understand common side effects of Immunotherapy and CDK 4/6 inhibitors.
• Describe differences between 2D and 3D mammography versus breast MRI and when it's appropriate to order each test.

Anthony Brandau, DO (he/him/his), Hematologist/Oncologist

Learning Objectives:

• Evaluate the efficacy of pharmacological interventions such as ACE-i, ARB, MCA, SGLT-2, GLP agonist in relation to slowing the progression of Chronic kidney disease
• Implement multimodal approaches for Chronic Kidney disease management, explore the benefits of integrated strategies including blood pressures reduction, dietary protein restriction and bicarbonate therapies, in conjunction with pharmacotherapies.
• Translate evidence based guidelines into clinical practice, analysis the current KDIGO guidelines for the management of Chronic Kidney Disease in diverse patient populations.

David I. Somerman, DO, FACOI (he/him/his), Nephrologist

David S. Levy, DO, FACOI, FASN (he/him/his), Assistant Professor of Clinical Medicine

Learning Objectives:

• Recognize the impact of social determinants of health on CKD risk and progression. 
• Identify lifestyle changes that have the potential to modify CKD risk and progression.
• Understand the importance of diet in mediating CKD risk and progression.

Andrew S. Chiao, DO (he/him/his), Nephrologist